Akamis Bio
Leading company in developing cancer gene therapies.
Launch date
Employees
Market cap
-
Enterprise valuation
€120—180m (Dealroom.co estimates May 2015.)
Company register number 06001442
Abingdon England (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 63.8m | <1m | <1m | 6.0m | <1m | - | <1m |
| % growth | - | (100 %) | 150 % | 817 % | (94 %) | - | - |
| EBITDA | 40.8m | (22.3m) | (20.6m) | (13.3m) | (20.8m) | (21.0m) | - |
| % EBITDA margin | 64 % | (8527 %) | (3148 %) | (221 %) | (5527 %) | - | - |
| Profit | 40.6m | (18.1m) | (18.6m) | (12.9m) | (19.3m) | (26.1m) | - |
| % profit margin | 64 % | (6928 %) | (2840 %) | (215 %) | (5137 %) | - | - |
| R&D budget | 14.6m | 20.9m | 18.5m | 14.3m | 17.1m | 16.8m | - |
| R&D % of revenue | 23 % | 7970 % | 2829 % | 239 % | 4549 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | N/A | Seed | |
£5.6m | Series A | ||
£3.6m | Early VC | ||
| N/A | £1.8m | Grant | |
£22.0m | Series B | ||
| N/A | $3.3m | Grant | |
£25.0m | Series C | ||
* | $30.0m | Convertible | |
| Total Funding | €99.9m | ||
Related Content
Recent News about Akamis Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.